Search

Your search keyword '"Novak, Anne J."' showing total 959 results

Search Constraints

Start Over You searched for: Author "Novak, Anne J." Remove constraint Author: "Novak, Anne J."
959 results on '"Novak, Anne J."'

Search Results

1. DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas

2. Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation

3. Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL

4. T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma

7. Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments

8. Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

9. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

10. Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes

11. Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study

12. Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

15. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL

16. Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

17. MicroRNA and long non-coding RNA analysis in IgM monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis

18. A genome-wide association study of marginal zone lymphoma shows association to the HLA region.

19. Genetics in Lymphomagenesis

21. Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma

22. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma

23. Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region

24. Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups

25. DEK Regulates B-Cell Proliferative Capacity and Is Associated with Aggressive Disease in Low-Grade B-Cell Lymphoma

26. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia

27. GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma

28. Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL

30. Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL

31. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

32. Molecular classification and identification of an aggressive signature in low‐grade B‐cell lymphomas

33. Abstract 1181: Etiologic heterogeneity of genetic risk for DLBCL cell-of origin molecular subtypes

34. Supplementary Figure from Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma

35. Supplementary Data from Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma

36. Data from Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma

37. Supplementary Figure 3 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies

38. Data from Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma

39. Supplementary Tables 1 and 2 from Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium

40. Data from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes

42. Supplementary Table 5 from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes

43. Supplementary Table 3 from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes

45. Supplementary Table 1 from Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma

46. Supplementary Figure 1 from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes

47. Supplementary Table 1 from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes

48. Supplementary Table 4 from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes

49. Supplementary Table 2 from Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes

Catalog

Books, media, physical & digital resources